BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 20955399)

  • 1. Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia.
    Pérez B; Kosmider O; Cassinat B; Renneville A; Lachenaud J; Kaltenbach S; Bertrand Y; Baruchel A; Chomienne C; Fontenay M; Preudhomme C; Cavé H
    Br J Haematol; 2010 Dec; 151(5):460-8. PubMed ID: 20955399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Molecular features of 109 patients with chronic myelomonocytic leukemia in a single center].
    Qu SQ; Pan LJ; Qin TJ; Xu ZF; Li B; Wang HJ; Sun Q; Jia YJ; Li CW; Cai WY; Gao QY; Jiao M; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2023 May; 44(5):373-379. PubMed ID: 37550186
    [No Abstract]   [Full Text] [Related]  

  • 3. Biallelic inactivation of the NF1 tumour suppressor gene in juvenile myelomonocytic leukaemia: Genetic evidence of driver function and implications for diagnostic workup.
    Ramamoorthy S; Lebrecht D; Schanze D; Schanze I; Wieland I; Andrieux G; Metzger P; Hess M; Albert MH; Borkhardt A; Bresters D; Buechner J; Catala A; De Haas V; Dworzak M; Erlacher M; Hasle H; Jahnukainen K; Locatelli F; Masetti R; Stary J; Turkiewicz D; Vinci L; Wlodarski MW; Yoshimi A; Boerries M; Niemeyer CM; Zenker M; Flotho C
    Br J Haematol; 2024 Feb; 204(2):595-605. PubMed ID: 37945316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia.
    Lipka DB; Witte T; Toth R; Yang J; Wiesenfarth M; Nöllke P; Fischer A; Brocks D; Gu Z; Park J; Strahm B; Wlodarski M; Yoshimi A; Claus R; Lübbert M; Busch H; Boerries M; Hartmann M; Schönung M; Kilik U; Langstein J; Wierzbinska JA; Pabst C; Garg S; Catalá A; De Moerloose B; Dworzak M; Hasle H; Locatelli F; Masetti R; Schmugge M; Smith O; Stary J; Ussowicz M; van den Heuvel-Eibrink MM; Assenov Y; Schlesner M; Niemeyer C; Flotho C; Plass C
    Nat Commun; 2017 Dec; 8(1):2126. PubMed ID: 29259247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammatory response in hematopoietic stem and progenitor cells triggered by activating SHP2 mutations evokes blood defects.
    Solman M; Blokzijl-Franke S; Piques F; Yan C; Yang Q; Strullu M; Kamel SM; Ak P; Bakkers J; Langenau DM; Cavé H; den Hertog J
    Elife; 2022 May; 11():. PubMed ID: 35535491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia.
    Patnaik MM; Tefferi A
    Blood Cancer J; 2016 Feb; 6(2):e393. PubMed ID: 26849014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia.
    Patnaik MM; Lasho TL; Vijayvargiya P; Finke CM; Hanson CA; Ketterling RP; Gangat N; Tefferi A
    Blood Cancer J; 2016 Jan; 6(1):e385. PubMed ID: 26771811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational landscape of chronic myelomonocytic leukemia in Chinese patients.
    Nie Y; Shao L; Zhang H; He CK; Li H; Zou J; Chen L; Ji H; Tan H; Lin Y; Ru K
    Exp Hematol Oncol; 2022 May; 11(1):32. PubMed ID: 35610628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Despite mutation acquisition in hematopoietic stem cells, JMML-propagating cells are not always restricted to this compartment.
    Caye A; Rouault-Pierre K; Strullu M; Lainey E; Abarrategi A; Fenneteau O; Arfeuille C; Osman J; Cassinat B; Pereira S; Anjos-Afonso F; Currie E; Ariza-McNaughton L; Barlogis V; Dalle JH; Baruchel A; Chomienne C; Cavé H; Bonnet D
    Leukemia; 2020 Jun; 34(6):1658-1668. PubMed ID: 31776464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Srsf2
    Xu JJ; Chalk AM; Wall M; Langdon WY; Smeets MF; Walkley CR
    Leukemia; 2022 Dec; 36(12):2883-2893. PubMed ID: 36271153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.
    Gelsi-Boyer V; Brecqueville M; Devillier R; Murati A; Mozziconacci MJ; Birnbaum D
    J Hematol Oncol; 2012 Mar; 5():12. PubMed ID: 22436456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morphologic and Immunophenotypic Differences in Juvenile Myelomonocytic Leukemias With CBL and Other Canonical RAS-pathway Gene Mutations: A Single Institutional Experience.
    Mariani RA; Jennings L; Zhang S; Bhat R; Gong S
    J Pediatr Hematol Oncol; 2021 Aug; 43(6):e819-e825. PubMed ID: 33769390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Clinical Landscape of NRAS- mutated Juvenile Myelomonocytic Leukemia-like Myeloproliferation Includes Children With Costello Syndrome.
    Pabari R; Chun K; Naqvi A
    J Pediatr Hematol Oncol; 2023 Apr; 45(3):e401-e405. PubMed ID: 35665722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases.
    Volchkov EV; Khozyainova AA; Gurzhikhanova MK; Larionova IV; Matveev VE; Evseev DA; Ignatova AK; Menyailo ME; Venyov DA; Vorobev RS; Semchenkova AA; Olshanskaya YV; Denisov EV; Maschan MA
    NPJ Syst Biol Appl; 2023 Sep; 9(1):41. PubMed ID: 37684264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia.
    Montalban-Bravo G; Kanagal-Shamanna R; Li Z; Hammond D; Chien K; Rodriguez-Sevilla JJ; Sasaki K; Jabbour E; DiNardo C; Takahashi K; Short N; Issa GC; Pemmaraju N; Kadia T; Ravandi F; Daver N; Borthakur G; Loghavi S; Pierce S; Bueso-Ramos C; Kantarjian H; Garcia-Manero G
    Br J Haematol; 2023 Nov; 203(4):581-592. PubMed ID: 37608562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical and genetic analyses of juvenile myelomonocytic leukemia].
    Zeng MH; He XL; Yang MH; Zheng MC; Wan WQ; Zou RY; Chen KK
    Zhongguo Dang Dai Er Ke Za Zhi; 2019 Apr; 21(4):365-369. PubMed ID: 31014430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic gene expression and epigenetic remodeling of cis-regulatory elements in ASXL1-mutant chronic myelomonocytic leukemia.
    Binder M; Carr RM; Lasho TL; Finke CM; Mangaonkar AA; Pin CL; Berger KR; Mazzone A; Potluri S; Ordog T; Robertson KD; Marks DL; Fernandez-Zapico ME; Gaspar-Maia A; Patnaik MM
    Nat Commun; 2022 Mar; 13(1):1434. PubMed ID: 35301312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia.
    Stieglitz E; Mazor T; Olshen AB; Geng H; Gelston LC; Akutagawa J; Lipka DB; Plass C; Flotho C; Chehab FF; Braun BS; Costello JF; Loh ML
    Nat Commun; 2017 Dec; 8(1):2127. PubMed ID: 29259179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic myeloproliferative neoplasm in adulthood in CBL syndrome harboring a splice-site
    Mason G; Aghajani R; Dance B; Othman J; Goodwin L; Stevenson W; Mackinlay N
    EJHaem; 2024 Apr; 5(2):397-402. PubMed ID: 38633130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term remission of infantile Takayasu arteritis associated with germline CBL syndrome after allogeneic hematopoietic stem cell transplantation: A case report and literature review.
    Munoz-Osores E; Piñones M; Barriga F; Wietstruck MA; Pérez-Mateluna G; Mellado C; Aracena M; Parra R; García C; Borzutzky A
    Transpl Immunol; 2024 Apr; 83():102013. PubMed ID: 38395087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.